IDH3A and glioblastoma: Even so, the prognosis for GBM patients is poor, especially for isocitrate dehydrogenase (IDH) wild-type, with a mean overall survival time of <14.6 months for newly diagnosed GBM patients and 6.9 months for recurrent GBM patients, the five-year survival rate of less than 10% (3).